InVitae (NYSE: NVTA) and Veracyte (NASDAQ:VCYT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

64.7% of InVitae shares are owned by institutional investors. Comparatively, 68.8% of Veracyte shares are owned by institutional investors. 9.9% of InVitae shares are owned by company insiders. Comparatively, 13.4% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for InVitae and Veracyte, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InVitae 0 0 3 0 3.00
Veracyte 0 2 3 0 2.60

InVitae presently has a consensus target price of $14.33, indicating a potential upside of 67.45%. Veracyte has a consensus target price of $12.50, indicating a potential upside of 89.39%. Given Veracyte’s higher probable upside, analysts plainly believe Veracyte is more favorable than InVitae.

Profitability

This table compares InVitae and Veracyte’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
InVitae -206.95% -115.25% -67.79%
Veracyte -38.19% -52.99% -29.50%

Volatility & Risk

InVitae has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500.

Earnings & Valuation

This table compares InVitae and Veracyte’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
InVitae $25.05 million 18.09 -$100.25 million ($2.56) -3.34
Veracyte $65.08 million 3.45 -$31.35 million ($0.81) -8.15

Veracyte has higher revenue and earnings than InVitae. Veracyte is trading at a lower price-to-earnings ratio than InVitae, indicating that it is currently the more affordable of the two stocks.

Summary

Veracyte beats InVitae on 10 of the 12 factors compared between the two stocks.

About InVitae

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company’s products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.

About Veracyte

Veracyte, Inc. is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. The Company’s commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis, centers on the Afirma Gene Expression Classifier (GEC). The Afirma GEC is offered directly or as part of a solution that also includes cytopathology. The Company operates in the pulmonology diagnostics market. It offers Percepta Bronchial Genomic Classifier, a genomic test to resolve ambiguity in lung cancer diagnosis. It also offers the Envisia Genomic Classifier, which is designed to help in the assessment of patients suspected to have idiopathic pulmonary fibrosis.

Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.